Citigroup
CTNM

Citigroup’s Contineum Therapeutics CTNM Stock Holding History

Citigroup’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$116K Sell
8,860
-3,464
-28% -$46.5K ﹤0.01% 4229
2025
Q4 		$141K Buy
+12,324
New +$141K ﹤0.01% 4159
2025
Q3 		– Sell
-1,774
Closed -$7.04K – 6360
2025
Q2 		$7.04K Sell
1,774
-5,613
-76% -$24.4K ﹤0.01% 5239
2025
Q1 		$51.6K Sell
7,387
-890
-11% -$8.1K ﹤0.01% 4860
2024
Q4 		$121K Buy
8,277
+3,395
+70% +$53.8K ﹤0.01% 4734
2024
Q3 		$93.4K Buy
4,882
+3,353
+219% +$64.3K ﹤0.01% 4791
2024
Q2 		$26.9K Buy
+1,529
New +$24.6K ﹤0.01% 4906

Other funds holding CTNM

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citigroup's CTNM Position: Q1 2026 in Review

Citigroup reduced its Contineum Therapeutics (CTNM) stake by 28% in Q1 2026, selling an estimated $46.5K and leaving 8,860 shares worth $116K. The position accounts for ﹤0.01% of the portfolio, ranked #4229.

Citigroup first reported a position in CTNM in Q2 2024 and has held it in 7 quarters since. The position peaked at $141K in Q4 2025. 90 funds tracked by Wall St. Rank hold CTNM as of Q1 2026.

  • Citigroup held 8,860 shares of Contineum Therapeutics worth $116K as of Q1 2026.
  • Citigroup sold 3,464 Contineum Therapeutics shares in Q1 2026, an estimated $46.5K.
  • Contineum Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #4229 holding.
  • Citigroup first reported a position in Contineum Therapeutics in Q2 2024 and has held it in 7 quarters since.
  • Citigroup's Contineum Therapeutics position peaked at $141K in Q4 2025.
  • 90 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.